These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3357926)

  • 1. R(-)-2,5-dimethoxy-4-77 bromoamphetamine [77Br-R(-)DOB]: a novel radioligand which labels a 5-HT binding site subtype.
    Wang SS; Mathis CA; Peroutka SJ
    Psychopharmacology (Berl); 1988; 94(3):431-2. PubMed ID: 3357926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (R)-(-)-[77Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes.
    Peroutka SJ; Hamik A; Harrington MA; Hoffman AJ; Mathis CA; Pierce PA; Wang SS
    Mol Pharmacol; 1988 Oct; 34(4):537-42. PubMed ID: 3173334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors.
    Lyon RA; Davis KH; Titeler M
    Mol Pharmacol; 1987 Feb; 31(2):194-9. PubMed ID: 3543649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of 5-hydroxytryptamine2 receptor subtypes using 125I-R-(-)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin.
    McKenna DJ; Peroutka SJ
    J Neurosci; 1989 Oct; 9(10):3482-90. PubMed ID: 2795135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT2 agonist radioligand.
    Titeler M; Lyon RA; Davis KH; Glennon RA
    Biochem Pharmacol; 1987 Oct; 36(19):3265-71. PubMed ID: 3663239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex.
    Pierce PA; Peroutka SJ
    Psychopharmacology (Berl); 1989; 97(1):118-22. PubMed ID: 2540505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for distinct 5-hydroxytryptamine2 binding site subtypes in cortical membrane preparations.
    Pierce PA; Peroutka SJ
    J Neurochem; 1989 Feb; 52(2):656-8. PubMed ID: 2911036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens.
    Titeler M; Lyon RA; Glennon RA
    Psychopharmacology (Berl); 1988; 94(2):213-6. PubMed ID: 3127847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonism of 5-hydroxytryptamine2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide.
    Pierce PA; Peroutka SJ
    J Pharmacol Exp Ther; 1988 Dec; 247(3):918-25. PubMed ID: 3204523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities.
    Sleight AJ; Stam NJ; Mutel V; Vanderheyden PM
    Biochem Pharmacol; 1996 Jan; 51(1):71-6. PubMed ID: 8534270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent agonist activity of DOB at 5-HT2 receptors in guinea pig trachea.
    Heller WA; Baraban JM
    Eur J Pharmacol; 1987 Jun; 138(1):115-7. PubMed ID: 3622603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.
    Titeler M; Herrick K; Lyon RA; McKenney JD; Glennon RA
    Eur J Pharmacol; 1985 Oct; 117(1):145-6. PubMed ID: 4085543
    [No Abstract]   [Full Text] [Related]  

  • 13. Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens.
    Lyon RA; Titeler M; Seggel MR; Glennon RA
    Eur J Pharmacol; 1988 Jan; 145(3):291-7. PubMed ID: 3350047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor.
    Branchek T; Adham N; Macchi M; Kao HT; Hartig PR
    Mol Pharmacol; 1990 Nov; 38(5):604-9. PubMed ID: 2233697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenethylamine hallucinogens in the locus coeruleus: potency of action correlates with rank order of 5-HT2 binding affinity.
    Rasmussen K; Glennon RA; Aghajanian GK
    Eur J Pharmacol; 1986 Dec; 132(1):79-82. PubMed ID: 3816969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain.
    Appel NM; Mitchell WM; Garlick RK; Glennon RA; Teitler M; De Souza EB
    J Pharmacol Exp Ther; 1990 Nov; 255(2):843-57. PubMed ID: 2243353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerance to LSD and DOB induced shaking behaviour: differential adaptations of frontocortical 5-HT(2A) and glutamate receptor binding sites.
    Buchborn T; Schröder H; Dieterich DC; Grecksch G; Höllt V
    Behav Brain Res; 2015 Mar; 281():62-8. PubMed ID: 25513973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse.
    Glennon RA; Titeler M; Lyon RA
    Pharmacol Biochem Behav; 1988 Jul; 30(3):597-601. PubMed ID: 3211969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs.
    Sanders-Bush E; Breeding M
    Psychopharmacology (Berl); 1991; 105(3):340-6. PubMed ID: 1665919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]ketanserin labeling of 5-hydroxytryptamine2 (5HT2) receptors in mammalian cells transfected with a rat 5HT2 cDNA: evidence for multiple states and not multiple 5HT2 receptor subtypes.
    Teitler M; Leonhardt S; Weisberg EL; Hoffman BJ
    Mol Pharmacol; 1990 Nov; 38(5):594-8. PubMed ID: 2233696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.